OVID - Ovid Therapeutics misses goal in Angelman syndrome treatment

Ovid Therapeutics (OVID) -44.8% post-market after saying its Phase 3 Neptune clinical trial of OV101 (gaboxadol) for the treatment of Angelman syndrome failed to meet its primary endpoint.The late-stage study was designed to assess the effects of treatment with OV101 vs. placebo over 12 weeks; the sole primary endpoint was change in overall score on the CGI-I-AS scale.Ovid plans to complete a full analysis of the results of the study and discuss the results with the Food and Drug Administration to determine next steps, if any, for the program.

For further details see:

Ovid Therapeutics misses goal in Angelman syndrome treatment